Sep 2026· Journal of Managed Care & Specialty Pharmacy· Vol 32 9, pp.
1122-1129
· 0 citations· 33 references
Medicine
TL;DR
A 4-layer framework can give MCOs earlier visibility into a therapy's likely clinical profile, cost-effectiveness distribution, and formulary placement probability before a manufacturer's dossier arrives, and allows budget forecasting and contracting strategy to keep pace with growing AI-accelerated pipelines.
Abstract
Artificial intelligence (AI) is rapidly compressing the timeline from molecular discovery to regulatory submission, meaning pipeline therapies will reach formulary committees faster and in greater numbers than ever before. For managed care organizations (MCOs), coverage and contracting decisions must be made earlier, especially for drug classes where the clinical and economic profile remains deeply uncertain. Yet the pipeline monitoring frameworks MCOs rely on, that is, static cost-effectiveness models, manufacturer dossiers, and binary pipeline assumptions, may not keep pace, leaving teams to evaluate therapies with limited visibility into the upstream uncertainty that shapes a drug's real-world value. No current framework links early AI-generated predictions of molecular performance to factors like formulary placement, rebate dynamics, and payer decision-making, leaving MCOs reactive at precisely the moment when anticipatory intelligence would be most valuable. This article proposes a probabilistic AI framework that carries uncertainty from molecular discovery through human trials, health economics, and managed care decision-making. The framework preserves and updates uncertainty across each stage rather than simplifying it into deterministic outcomes. By integrating molecular modeling, Bayesian clinical forecasting, dynamic health economic modeling, and negotiation simulations, the framework can generate early forecasts of formulary placement, cost-effectiveness profile, and more. This article uses lesinurad as an illustrative case study of how drugs can clear every preclinical and regulatory hurdle yet still fail at the formulary-precisely the kind of late-stage surprise anticipatory intelligence is designed to prevent. The 4-layer framework can give MCOs earlier visibility into a therapy's likely clinical profile, cost-effectiveness distribution, and formulary placement probability before a manufacturer's dossier arrives. Such a framework allows budget forecasting and contracting strategy to keep pace with growing AI-accelerated pipelines.
A critical review is needed to distinguish the stages in which AI can improve search, prioritization, and decision-making from those that remain limited by experimental validation, safety assessment, and clinical evidence generation.
J. Fernández-Martínez· Expert Opinion on Drug Disco...· 0 citations
Predictive safety is used primarily to mean product-level and population- or subgroup-level anticipation of plausible treatment-related harm, rather than an autonomous patient-level clinical decision-making approach.
Tarek A. Hammad, Justine Rochon, Kate Gofman et al.· Drug Safety· 0 citations
Recommendations are provided for the development of AI in drug discovery with the aim of increasing its translational relevance, including benchmarking studies of AI tools in drug discovery need to move on from model validation and instead focus on their ability to improve decision making.
Andreas Bender, Morgan C. Thomas, J. Scannell et al.· Nature reviews. Drug discove...· 10 citations
This review discusses agentic AI applications across the drug development continuum, from target discovery to post-market surveillance, and highlights three near-term use cases: algorithmic drug repurposing, informed consent support and automated drafting of regulatory documents.
Sheraz Khan, John G. Samuelsson, Xue-Mei Cai et al.· Drug Discovery Today· 0 citations
This work addresses one of the most pervasive obstacles to applying AI in real-world drug development by addressing conformal prediction framework tailored to label shift by weighting conformal scores using marginal label probability ratios and enhancing the trustworthiness of AI-driven predictions.
Hyeonsu Lee, Juyeong Kim, Erkhembayar Jadamba et al.· 2 citations
This work presents a model validation framework consisting of five recommendations that would enable the community to move beyond aggregate metrics toward understanding where and why molecular property prediction models fail, and connects evaluation choices to real-world applications and case studies encountered in pha...
Srijit Seal, Akshat Shirish Zalte, David Alencar Araripe et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.